Search

465 Result(s)
Sort by

Patient voices Augustos story

Patient voices Augustos story

Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Eves story

Patient voices Eves story

Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Ulrichs story

Patient voices Ulrichs story

Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Transforming pig farming through AI

Transforming pig farming through AI

With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
Daniel Kiesenhofer

Daniel Kiesenhofer

Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim
Dirk Esser

Dirk Esser

Diverse, caring, collaborative - Dirk Esser on Boehringer Ingelheim
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Living With Cancer

Living With Cancer

Every cancer journey is unique. Listen to the first-hand experiences of people living with cancer.
EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Ann-Kathrin Koller

Ann-Kathrin Koller

Diverse, caring, collaborative - Ann-Kathrin Koller on Boehringer Ingelheim
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Isabel

Isabel

In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.